Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Beuvry – page 79

1 417 clinical trials in Beuvry, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Beuvry at a glance
1 417
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 417 trials in Beuvry

Open in trial search

Frontotemporal dementia

Not recruiting

Study on the Safety and Effects of LY3884963 for Patients with Fronto-Temporal Dementia with Progranulin Mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Prevail Therapeutics Inc.

Glioma

Not recruiting

Study of Abemaciclib and Temozolomide for Children and Young Adults with Newly Diagnosed High-Grade Glioma After Radiotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Diabetic retinopathy+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Bayer AG

Glycogen storage disease type II

Not recruiting

Long-Term Safety Study of Avalglucosidase Alfa for Patients with Pompe Disease in France

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Avalglucosidase Alfa
  • Sponsor:Sanofi Winthrop Industrie

Pemphigoid

Not recruiting

Study of dupilumab effectiveness compared to placebo in adults with bullous pemphigoid

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Prostate cancer

Not recruiting

Study on Darolutamide with Radiation Therapy for Patients with Intermediate Unfavorable Risk Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Institut Bergonie

Peripheral T-cell lymphoma unspecified

Not recruiting

Study of Lacutamab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:LYSARC

Endometrial cancer

Not recruiting

Study Comparing Sentinel Node Policy with Current Staging Protocols in Early Stage Endometrial Cancer Using Patent Blue, Technetium (99mTc) Rheniumsulfide, and Indocyanine Green

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Indocyanine Green
  • Sponsor:Centre Oscar Lambret

Asplenia

Not recruiting

Study on the Safety and Immune Response of Meningococcal B Vaccines in Adults with Asplenia: Bexsero, Trumenba, and a Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Assistance Publique Hopitaux De Paris

Medical device site joint infection

Not recruiting

Study of PP1493 and PP1815 bacteriophages combined with DAIR and antibiotics for treating knee or hip prosthetic joint infections caused by Staphylococcus aureus

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Phaxiam Therapeutics

Retinoblastoma

Not recruiting

Study on Adjuvant Treatment for Unilateral Retinoblastoma with Vincristine Sulfate and Drug Combination in Patients After Primary Eye Removal

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:Institut Curie

General physical health deterioration+1

Not recruiting

Study on Durvalumab for Patients with Poor General Condition and Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Beuvry

What the registry says about research in the country

01 Oncology Research - Digestive System

Several groundbreaking trials focusing on gastrointestinal cancers, including studies evaluating novel treatments for esophageal squamous cell carcinoma and advanced colorectal cancer. Research includes innovative combination therapies and targeted treatments for specific genetic mutations.

  • Esophageal Cancer Treatment
  • Colorectal Cancer Therapies
  • Pancreatic Adenocarcinoma Studies
02 Respiratory and Lung Cancer Research

Innovative studies examining treatments for non-small cell lung cancer, including immunotherapy combinations and radiation therapy approaches. Research focuses on improving outcomes for patients with advanced disease stages.

  • Advanced NSCLC Treatments
  • Immunotherapy Combinations
  • Radiation Therapy Protocols
03 Prostate and Breast Cancer Studies

Comprehensive research into hormone-dependent cancers, investigating new treatment approaches for castrate-resistant prostate cancer and ER+/HER2- breast cancer. Studies include both early-stage and advanced disease management.

  • Prostate Cancer Therapeutics
  • Breast Cancer Treatments
  • Hormone Therapy Research
04 Infectious Disease and Critical Care

Studies examining treatments for respiratory tract infections and severe infections in intensive care settings. Research includes antibiotic alternatives and management strategies for septic shock.

  • Respiratory Infections
  • Antibiotic Studies
  • Critical Care Interventions
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.